Interaksi Piroksikam

Piroksikam (Feldene), golongan OAINS, memiliki 256 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 50 mayor, 197 moderat, 9 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (50)

  • ApiksabanantikoagulanMayor

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (label Apiksaban, Peringatan kotak hitam)

  • Asam mefenamatOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • AspirinOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • Aspirin dan dipiridamolantiplateletMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • BalsalazidsalisilatMayor

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (label Piroksikam, Interaksi obat)

  • Bismut subsalisilatsalisilatMayor

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (label Piroksikam, Interaksi obat)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • DabigatranantikoagulanMayor

    …the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (label Dabigatran, Peringatan kotak hitam)

  • DiflunisalOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • DiklofenakOAINSMayor

    NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (label Piroksikam, Interaksi obat)

  • NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (label Piroksikam, Interaksi obat)

  • EdoksabanantikoagulanMayor

    …the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (label Edoksaban, Peringatan kotak hitam)

  • Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (label Efavirenz, lamivudin, dan tenofovir, Peringatan dan perhatian)

  • COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (label Emtrisitabin, rilpivirin, dan tenofovir, Peringatan dan perhatian)

  • EnoksaparinantikoagulanMayor

    …the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (label Enoksaparin, Peringatan kotak hitam)

  • EtodolakOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • FenoprofenOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • FlurbiprofenOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • FondaparinuksantikoagulanMayor

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (label Fondaparinuks, Peringatan kotak hitam)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • IbuprofenOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • IndometasinOAINSMayor

    NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (label Piroksikam, Interaksi obat)

  • KetoprofenOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • KetorolakOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • MeloksikamOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (label Piroksikam, Interaksi obat)

  • MesalazinsalisilatMayor

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (label Piroksikam, Interaksi obat)

  • MetotreksatimunosupresanMayor

    Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (label Metotreksat, Peringatan dan perhatian)

  • Misoprostolanalog prostaglandinMayor

    MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (label Misoprostol, Peringatan kotak hitam)

  • Montelukastantagonis reseptor leukotrienMayor

    Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (label Montelukast, Peringatan dan perhatian)

  • NabumetonOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • NaproksenOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • OksaprozinOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • PemetreksedantimetabolitMayor

    NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (label Piroksikam, Interaksi obat)

  • PralatreksatantimetabolitMayor

    Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (label Pralatreksat, Interaksi obat)

  • PrasugrelantiplateletMayor

    Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (label Prasugrel, Peringatan kotak hitam)

  • RivaroksabanantikoagulanMayor

    …risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (label Rivaroksaban, Peringatan kotak hitam)

  • SalsalatOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • SelekoksibOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • SidofovirantivirusMayor

    Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (label Sidofovir, Interaksi obat)

  • SulfasalazinsulfonamidaMayor

    Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (label Piroksikam, Interaksi obat)

  • SulindakOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

  • TenofovirantiretroviralMayor

    VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (label Tenofovir, Peringatan dan perhatian)

  • TolmetinOAINSMayor

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (label Piroksikam, Kontraindikasi)

Interaksi moderat (197)

  • AdefovirantivirusModerat

    However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (label Adefovir, Peringatan dan perhatian)

  • AfatinibModerat

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (label Afatinib, Peringatan dan perhatian)

  • AlendronatbisfosfonatModerat

    Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (label Alendronat, Interaksi obat)

  • AliskirenantihipertensiModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • AlkoholAlkoholModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Alprostadilanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • Amiloriddiuretik hemat kaliumModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTModerat

    Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (label Anagrelid, Peringatan dan perhatian)

  • ArgatrobanantikoagulanModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Asam zoledronatbisfosfonatModerat

    Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (label Asam zoledronat, Interaksi obat)

  • Asebutololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Atenololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Atenolol dan klortalidonpenyekat betaModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Atomoksetinpenghambat ambilan kembali norepinefrinModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Benazeprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • BetametasonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Bimatoprostanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • BivalirudinantikoagulanModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (label Piroksikam, Interaksi obat)

  • BudesonidkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Bumetaniddiuretik loopModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Dapagliflozinpenghambat SGLT2Moderat

    …↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (label Dapagliflozin, Interaksi obat)

  • Deferasirokssuplemen zat besiModerat

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (label Deferasiroks, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (label Desmopresin, Interaksi obat)

  • DesonidkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • DesvenlafaksinSNRIModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Digoksinglikosida digitalisModerat

    Digoxin: Concomitant use of Piroxicam Capsules can increase serum concentration and prolong half-life of digoxin. (label Piroksikam, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Dinoprostonanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • DipiridamolantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Doksazosinpenyekat alfaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Donepezilpenghambat kolinesteraseModerat

    Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (label Donepezil, Peringatan dan perhatian)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (label Piroksikam, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (label Drospirenon dan etinilestradiol, Peringatan dan perhatian)

  • DuloksetinSNRIModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Peringatan dan perhatian)

  • Emtrisitabin dan tenofovirantiretroviralModerat

    Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (label Emtrisitabin dan tenofovir, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Enalaprilatpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Epoprostenolanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • EptifibatidantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • ErlotinibModerat

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (label Erlotinib, Peringatan dan perhatian)

  • EsitalopramSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (label Piroksikam, Interaksi obat)

  • Febuksostatpenghambat xantin oksidaseModerat

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (label Febuksostat, Peringatan dan perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Fenoksibenzaminpenyekat alfaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • FludrokortisonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Flukonazolantijamur azolModerat

    Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (label Flukonazol, Interaksi obat)

  • FlunisolidkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • FluoksetinSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • FluvoksaminSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Fosinoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Furosemiddiuretik loopModerat

    Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. (label Piroksikam, Interaksi obat)

  • Galantaminpenghambat kolinesteraseModerat

    Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

  • GlibenklamidsulfonilureaModerat

    Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (label Glibenklamid, Interaksi obat)

  • GlimepiridsulfonilureaModerat

    …steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (label Glimepirid, Interaksi obat)

  • GlipizidsulfonilureaModerat

    …angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (label Glipizid, Interaksi obat)

  • Glipizid dan metforminsulfonilureaModerat

    Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (label Glipizid dan metformin, Perhatian)

  • Guanfasinagonis alfa-adrenergikModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • HalobetasolkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • HeparinantikoagulanModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • HidralazinvasodilatorModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Hidroklorotiaziddiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • IbandronatbisfosfonatModerat

    Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (label Ibandronat, Interaksi obat)

  • Indapamiddiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Itrakonazolantijamur azolModerat

    Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (label Itrakonazol, Interaksi obat)

  • Kalium kloridasuplemen kaliumModerat

    Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (label Kalium klorida, Interaksi obat)

  • Kalium sitratsuplemen kaliumModerat

    Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (label Kalium sitrat, Interaksi obat)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • KangrelorantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Karboprostanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • KlobetasolkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Klonidinagonis alfa-adrenergikModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • KlopidogrelantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Labetalolpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Latanoprostanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • LevofloksasinfluorokuinolonModerat

    Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (label Levofloksasin, Interaksi obat)

  • LevomilnasipranSNRIModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Litiumobat serotonergikModerat

    Lithium Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. (label Piroksikam, Interaksi obat)

  • Lofeksidinagonis alfa-adrenergikModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Memantin dan donepezilpenghambat kolinesteraseModerat

    Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (label Memantin dan donepezil, Peringatan dan perhatian)

  • MetildopaantihipertensiModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • MetilprednisolonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Metolazondiuretik tiazidModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Moderat

    When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (label Mifepriston, Interaksi obat)

  • MilnasipranSNRIModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • MinoksidilvasodilatorModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Moeksiprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • MoksifloksasinfluorokuinolonModerat

    Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (label Moksifloksasin, Interaksi obat)

  • MometasonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • NateglinidmeglitinidModerat

    Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (label Nateglinid, Interaksi obat)

  • Nebivololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • NintedanibModerat

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (label Nintedanib, Peringatan dan perhatian)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • NitroprusidvasodilatorModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • OfloksasinfluorokuinolonModerat

    Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (label Ofloksasin, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • ParoksetinSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • PentoksifilinmetilxantinModerat

    DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (label Pentoksifilin, Interaksi obat)

  • Perindoprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Pindololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    …steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (label Pioglitazon dan glimepirid, Interaksi obat)

  • Prazosinpenyekat alfaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • PrednisolonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • Ramiprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Rivastigminpenghambat kolinesteraseModerat

    Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (label Rivastigmin, Peringatan dan perhatian)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • SefotaksimsefalosporinModerat

    Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (label Sefotaksim, Interaksi obat)

  • SertralinSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Cyclosporine Clinical Impact: Concomitant use of Piroxicam Capsules and cyclosporine may increase cyclosporine's nephrotoxicity. (label Piroksikam, Interaksi obat)

  • SilostazolantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • SiprofloksasinfluorokuinolonModerat

    NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (label Siprofloksasin, Interaksi obat)

  • SitalopramSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Solriamfetolstimulan SSPModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (label Piroksikam, Interaksi obat)

  • Spironolaktonantagonis aldosteronModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Tembakau dan merokokTembakau dan ganjaModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • TikagrelorantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Timololpenyekat betaModerat

    Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (label Piroksikam, Interaksi obat)

  • TirofibanantiplateletModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Tizanidinpelemas ototModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • TofasitinibimunosupresanModerat

    Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (label Tofasitinib, Peringatan dan perhatian)

  • Torasemiddiuretik loopModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • TrazodonantidepresanModerat

    Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (label Trazodon, Peringatan dan perhatian)

  • Treprostinilanalog prostaglandinModerat

    Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (label Piroksikam, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • UpadasitinibimunosupresanModerat

    Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (label Upadasitinib, Peringatan dan perhatian)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (label Piroksikam, Peringatan dan perhatian)

  • VenlafaksinSNRIModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (label Piroksikam, Interaksi obat)

  • VilazodonSSRIModerat

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (label Piroksikam, Peringatan dan perhatian)

  • Viloksazinpenghambat ambilan kembali norepinefrinModerat

    Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (label Piroksikam, Peringatan dan perhatian)

  • Vorikonazolantijamur azolModerat

    NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (label Vorikonazol, Interaksi obat)

  • VortioksetinantidepresanModerat

    • Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (label Vortioksetin, Peringatan dan perhatian)

  • WarfarinantikoagulanModerat

    Drugs that Interfere with Hemostasis (e.g. warfarin, aspirin, selective serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake inhibitors [SNRIs]): Monitor patients for bleeding who are concomitantly taking Piroxicam Capsules with drugs that interfere with hemostasis. (label Piroksikam, Interaksi obat)

Penyebutan minor (9)

  • Finasteridpenghambat 5-alfa reduktaseMinor

    …angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (label Finasterid, Interaksi obat)

  • Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (label Glibenklamid dan metformin, Interaksi obat)

  • InfliksimabimunosupresanMinor

    In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (label Infliksimab, Interaksi obat)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (label Lenalidomid, Peringatan dan perhatian)

  • Levotiroksinhormon tiroidMinor

    Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (label Levotiroksin, Interaksi obat)

  • Liotironinhormon tiroidMinor

    Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (label Liotironin, Interaksi obat)

  • RepaglinidmeglitinidMinor

    Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (label Repaglinid, Interaksi obat)

  • RisedronatbisfosfonatMinor

    Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (label Risedronat, Interaksi obat)

  • TosilizumabimunosupresanMinor

    Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (label Tosilizumab, Interaksi obat)

Periksa Piroksikam terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.